ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024
29 Novembre 2024 - 8:00PM
Business Wire
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world’s only
natural recombinant apoA-I, announces that all resolutions
presented at its Combined General Meeting on November 28th, 2024,
were approved.
Among the resolutions adopted were the appointment of
Jean-Gérard Galvez, Luc Demarre and Caroline DeSurmont as directors
for a 4-year term. The ABIONYX Board of Directors now comprises
three women out of eight members, in compliance with the applicable
rules, and includes four independent members. Shareholders also
approved the proposed financial delegations necessary for the
Company’s development, as well as the proposed amendments to the
bylaws, in particular to revise the rules governing declarations of
crossing statutory thresholds, extend the terms of office of
directors and introduce double voting rights.
ABIONYX Pharma would like to thank all shareholders present,
represented or having voted by post for their commitment and
support at this General Meeting.
The minutes of the General Meeting, the replay of the General
Meeting and the results of the votes by resolution are available on
the Company's website in the Shareholder Meeting section.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines for diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated
apoA-I-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in Sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241129930203/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 94 94
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
